Cincinnati Children’s Led Study Identifies Maternal Antibodies as Critical Defense Against Neonatal E. Coli Infection

Cincinnati Children’s study finds that maternal antibodies protect most babies from E. coli, opening doors for new screening tests and probiotic treatments.

By: AXL Media

Published: Mar 13, 2026, 8:33 AM EDT

Source: Information for this report was sourced from Cincinnati Children's Hospital Medical Center

Maternal Immunity Solves Long-Standing Neonatal Infection Puzzle

A major investigation led by experts at Cincinnati Children’s has provided a definitive answer to why only a small fraction of infants suffer from severe Escherichia coli infections despite nearly universal exposure. The study, published in the journal Nature, demonstrates that the vast majority of newborns are shielded by antibodies they receive from their mothers in the womb. E. coli remains a leading cause of neonatal sepsis, yet it only affects approximately 1 in 1,000 live births. This research highlights that the rare instances of severe illness occur almost exclusively in babies who have markedly lower levels of these transferred maternal antibodies.

Analyzing Real-World Data via Newborn Screening Samples

To reach these conclusions, a global team of investigators utilized an innovative research method involving dried blood samples from routine newborn screenings. The team analyzed samples from 100 infants who eventually developed E. coli infections and compared them to hundreds of healthy controls. The results were consistent: babies who succumbed to infection lacked the specific germ-fighting antibodies that target the diverse strains of E. coli. Dr. Sing Sing Way, a senior author of the study, noted that while the immune systems of newborns are naturally immature, the natural transfer of antibodies during pregnancy provides a critical safety net that most infants rely on for survival.

Probiotic Interventions and the Potential for Enhanced Protection

In conjunction with human data, researchers conducted experimental trials using mouse models to explore preventative strategies. Because lab mice are often raised in germ-free environments, they typically lack the antibodies necessary to fight E. coli. The team found that introducing a specific probiotic strain, E. coli Nissle 1917, to female mice prior to pregnancy successfully stimulated the production of protective antibodies. These antibodies were then passed to the offspring, effectively shielding them from infection. This probiotic, already available for human use in several countries under the name Mutaflor, represents a potential bridge for restoring missing maternal defenses.